ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Nurix and Sanofi sign $50 million pact on targeted protein degradation

by Michael McCoy
January 10, 2020 | APPEARED IN VOLUME 98, ISSUE 2

 

Sanofi will pay Nurix Therapeutics $55 million up front and up to $2.5 billion in future milestones to collaborate on targeted protein degradation therapies. Nurix will use DNA-encoded libraries and E3 ligases to create small molecules designed to induce degradation—rather than mere inhibition—of three specified protein drug targets. Nurix signed a similar deal with Gilead Sciences in June that was focused on cancer and other diseases. Biotech firms like Arvinas and Kymera Therapeutics are also developing protein degraders

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment